Houston startup completes testing, prepares biosimilar insulin drug for clinical trials

next steps

A Houston-based biotech company has completed early testing for its groundbreaking insulin alternative and is headed toward clinical trials. Photo via Getty Images

A Houston biotech startup is one step closer to releasing its marquee drug for the global insulin market, which is projected to break the $90 billion threshold by 2029.

rBIO says it recently completed testing of the properties of R-biolin, an insulin drug that’s biologically identical to Novo Nordisk’s Novolin drug. The patent for Novolin about two decades ago. In March 2023, the Dutch drugmaker announced it was slashing the list price of Novolin by 65 percent to $48.20 per vial and $91.09 per FlexPen.

Executives at rBIO are now pursuing a partnership with a contract research organization to manage clinical trials of R-biolin. If those trials go well, R-biolin will seek approval to supply its insulin therapy to diabetes patients around the world.

Washington University in St. Louis is rBIO’s academic partner for the R-biolin project.

The rBIO platform produces insulin at greater yields that traditional manufacturing techniques do. The company is striving to drive down the cost of insulin by 30 percent.

About 38 million Americans have diabetes, with the vast majority being treated for type 2 diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). Many people with diabetes must take insulin to control their blood sugar levels.

Research company iHealthcareAnalyst predicts the global market for insulin will surpass the $90 billion mark in 2029.

“There has been a lot of talk in the media about reducing the cost of insulin for diabetic patients, but what is often overlooked is that the domestic demand for insulin will soon outpace the supply, leading to a new host of issues,” Cameron Owen, co-founder and CEO of rBIO, says in a news release.

“We’re dedicated to addressing the growing demand for accessible insulin therapies, and … we’re thrilled to announce the viability of our highly scalable manufacturing process.”

Professionals from the University of California San Diego and Johns Hopkins University established rBIO in 2020. The startup moved its headquarters from San Diego to Houston in 2022.

CEO Cameron Owen and Chief Scientific Officer Deenadayalan Bakthavatsalam work on insulin purification in the Houston lab. Photo courtesy

This week's roundup of Houston innovators includes Gaurab Chakrabarti of Solugen, Sandy Guitar of HX Venture Fund, and Cameron Owen of rBIO. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from synthetic biology to venture capital — recently making headlines in Houston innovation.

Gaurab Chakrabarti, the CEO and co-founder of Solugen

Gaurab Chakrabarti shared his entrepreneurial journey on the SXSW stage this year. Photo courtesy of the Greater Houston Partnership

Houston doesn't have too many unicorns — startups valued at $1 billion or more — in its innovation ecosystem, but Solugen, a sustainable chemicals company, is among the elite group. Gaurab Chakrabarti, the CEO and co-founder of the company, joined Houston House by the Greater Houston Partnership, to share his story on the SXSW stage.

“You do make your own luck, but you have to be putting in the work to do it," Chakrabarti says, adding that it's not an easy thing to accomplish. “There are things you can be doing to increase your luck surface area."

He shared several lessons he learned on his founder journey in the discussion. Read more.

Sandy Guitar, managing director of HX Venture Fund

Sandy Guitar shares some lessons learned from the fallout of Silicon Valley Bank. Photo via HXVF

Following the failure of Silicon Valley Bank, there's one thing Sandy Guitar can say has changed for Houston innovators: Bank diversification is going to be a must.

“We didn't think we needed one last week, but this week we know we need a resilience plan," she says, explaining that bank diversification is going to be added to "the operational due diligence playbook." Read more.

Cameron Owen, co-founder and CEO of rBIO

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo courtesy of rBIO

Founded in San Diego, rBIO recently relocated to Houston and has big plans for settling in the city, says Cameron Owen, the company's co-founder and CEO.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

He shares that Houston wasn't originally on his radar, until it was. A visit turned into a relocation, and it's just the beginning for the biotech startup that's focused on using synthetic biology for pharmaceuticals. Read more.

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo via Getty Images

California-founded biotech startup relocates to join Houston's emerging bioeconomy

new to hou

Cameron Owen had an idea for a synthetic biology application, and he pitched it to a handful of postdoctoral programs. When he received the feedback that he didn't have enough research experience, he decided to launch a startup based in San Diego around his idea. He figured that he'd either get the experience he needed to re-apply, or he'd create a viable company.

After three years of research and development, Owen's path seems to have taken him down the latter of those two options, and he moved his viable company, rBIO, to Houston — a twist he didn't see coming.

“Houston was not on my radar until about a year and a half ago,” Owen says, explaining that he thought of Houston as a leading health care hub, but the coasts still had an edge when it came to what he was doing. “San Diego and the Boston area are the two big biotech and life science hubs.”

But when he visited the Bayou City in December of 2021, he says he saw first hand that something new was happening.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

Owen moved to Houston last year, but rBIO still has an academic partner in Washington University in St. Louis and a clinical research organization it's working with too, so he admits rBIO's local footprint is relatively small — but not for long.

"When we look to want to get into manufacturing, we definitely want to build something here in Houston," he says. "We’re just not to that point as a company."

In terms of the stage rBIO is in now, Owen says the company is coming out of R&D and into clinical studies. He says rBIO has plans to fundraise and is meeting with potential partners that will help his company scale and build out a facility.

With the help of its CRO partner, rBIO has two ongoing clinical projects — with a third coming next month. Owen says right now rBIO is targeting the pharmaceutical industry’s biologics sector — these are drugs our bodies make naturally, like insulin. About 12 percent of the population in the United States has diabetes, which translates to almost 40 million people. The demand for insulin is high, and rBIO has a way to create it — and at 30 percent less cost.

This is just the tip of the iceberg — the world of synthetic biology application is endless.

“Now that we can design and manipulate biology in ways we’ve never been able to before,” Owen says, "we’re really only limited by our own imagination.”

Synthetic biology is a field of science that involves programing biology to create and redesign natural elements. While it sounds like science fiction, Owen compares it to any other type of technology.

“Biology really is a type of software,” he says. “Phones and computers at their core run on 1s and 0s. In biology, it’s kind of the same thing, but instead of two letters, it’s four — A, C, T, and G.”

“The cool thing about biology is the software builds the hardware,” he continues. “You put that code in there and the biology builds in and of itself.”

Owen says the industry of synthetic biology has been rising in popularity for years, but the technology has only recently caught up.

“We’re exploring a brave new world — there’s no doubt about that,” Owen says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University launches AI initiative, plans to hire 75 faculty

ai expansion

Houston’s Rice University announced a university-wide artificial intelligence initiative this week that includes hiring 75 new AI-focused faculty. It also shared new details about its planned state-of-the-art facility, The Arc.

Fresh off the announcement of Rice’s new Master of Artificial Intelligence (MAI) coming next fall, the university shared that it plans to expand its AI-related courses and be a “global leader in advanced computing and responsible AI.”

Rice reports that it has already hired 35 faculty members to deepen expertise across schools and departments regarding AI, and plans to recruit 40 more across disciplines including engineering, computing, health, energy, environmental resilience, business, humanities and the arts.

Rice's schools and departments have identified the four cluster areas to guide its hiring:

  • Foundational AI
  • AI for Health
  • AI for Energy, the Environment and Resiliency
  • Responsible AI: Society and Ethics

“Hiring exceptional faculty is essential, but it is only one part of the equation,” Amy Dittmar, Rice’s Howard R. Hughes Provost and executive vice president for academic affairs, said in a news release. “We are building the people, places and partnerships needed to advance AI from foundational discovery to societal impact.”

Another major component of the effort is the planned 200,000-square-foot facility, The Arc, which Rice announced will break ground this fall. Rice will occupy nearly 80,000 square feet of office and laboratory space dedicated to topics including AI, data science, robotics, computational engineering and energy. The university previously announced that The Arc would be completed in Q1 2028.

The Arc will also house the AI Foundry, which is being developed as a collaborative space for industry partners, scientists and students.

“As Rice grows, we are being intentional about where we invest and how we build,” Rice President Reginald DesRoches added in the release. “By bringing together exceptional faculty, a strong interdisciplinary research community, world-class facilities and Houston’s extraordinary innovation ecosystem, Rice has an opportunity not simply to participate in the AI revolution but to help define its future.”

5 minority-founded startups shaping the future of Houston innovation

meet the finalists

Houston’s startup ecosystem reflects the diversity of the city itself.

As part of the 2026 Houston Innovation Awards, our Minority-founded Businesses category will honor an innovative Houston startup founded or co-founded by BIPOC or LGBTQ+ representation.

Five minority-founded businesses have been named finalists for the 2026 award. The finalists, selected by our esteemed panel of judges, range from an AI edtech startup to a company operating in the floating offshore energy infrastructure sector.

Read more about these innovative businesses, their initiatives, and their inspirational founders below. The 2026 winners will be announced on InnovationMap.com in mid-November.

AI Made Fun

Edtech startup AI Made Fun is working to close the gap in AI education by teaching K-12 students how to understand and responsibly use artificial intelligence. The company has developed a comprehensive AI literacy curriculum with 60 modules, animated videos, interactive activities, teacher guides and family resources. Its curriculum covers how AI works, misinformation, algorithmic bias, data privacy, online safety and academic integrity.

AI Made Fun was founded in 2025 by Devshree Golecha. It launched in classrooms this school year with five licensed schools serving more than 800 students. The company is pursuing partnerships with Houston-area school districts, including Houston ISD and Alief ISD, and has pledged free and subsidized access for underserved communities.

Deep Anchor Solutions

Offshore energy consulting and design company Deep Anchor Solutions wants to help scale floating offshore energy infrastructure by removing anchoring as a barrier. Its deeply embedded ring anchor (DERA) technology can be installed quietly without heavy-lift vessels, reducing anchor-related costs by up to 75 percent and lifecycle CO2 emissions by up to 80 percent.

The company was founded in 2023 by CEO Junho Lee and technical advisor Charles Aubeny. Lee earned his Ph.D. in geotechnical engineering from Texas A&M University, where Aubeny is a professor of civil and environmental engineering. The company has participated in numerous accelerators and incubators, including Greentown Labs, MassChallenge, EnergyTechNexus LiftOff and others. Lee was an Activate 2025 fellow.

HEXAspec

Rice University spinout HEXASpec is working to improve the sustainability and thermal conductivity of semiconductor chips. The company has developed breakthrough inorganic fillers that allow graphic processing units (GPUs) to use less water and electricity and generate less heat.

HEXASpec was founded in 2025 by CEO Tianshu Zhai, CTO Jing Zhang and chief product officer Chen-Yang Lin. It has raised $800,000 in pre-seed funding and another $1.5 million in non-dilutive grants, according to the company's application. The startup won the Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge in 2024 and the 2025 Energy Venture Day and Pitch Competition during CERAWeek in the TEX-E student track in 2025. It was awarded a $500,000 National Science Foundation Partnership for Innovation grant last summer.

Prana Surgical

Health tech company Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Torres Orbital Mining Inc.

Space tech company Torres Orbital Mining is developing autonomous excavation and material preprocessing systems to move and process granular materials while reducing workers’ exposure to hazardous dust. The company is initially commercializing its technology for Earth-bound applications—including silica sand, recycled glass and mine tailings—though the technology is also designed to support future lunar mining operations. The company aims to accelerate a permanent and ethical human presence on the Moon.

CEO Luis Torres founded Torres Orbital Mining in 2025. The company is a member of Greentown Labs and has participated in accelerators like the ESRIC Space Resources Startup Program and Capital Factory All Access Fund. The company received a six-month, $225,000 SBIR Phase I contract from NASA in August.

Italian aerospace company sets up first U.S. office at Houston Spaceport

welcome to houston

Como, Italy-based aerospace company Involve Space recently made the Houston Spaceport the site of its first U.S. office.

Involve Space develops high-altitude balloon platforms for Earth observation, scientific research and hardware testing. The balloons carry instruments into the stratosphere (a layer of the upper atmosphere) to collect images and data, conduct experiments and test technology.

The company plans to launch its first commercial missions from Houston by the end of this year, according to a news release.

“Houston is the global center of aerospace, and our presence at Houston Spaceport strengthens our international growth trajectory,” Jonathan Polotto, founder and CEO of Involve Space, said in the release.

Founded in 2021, Involve Space incorporates aerospace hardware, AI and geospatial tools into its offerings. Its proprietary CLEAR platform uses conversational AI to help customers interpret data and support decision-making.

Located at Ellington Airport, the Houston Spaceport provides a base for Involve Space’s North American operations, including business development and partnerships with aerospace companies and researchers.

Other tenants at the Houston Spaceport include NASA, Axiom Space, Venus Aerospace and Intuitive Machines.

Involve Space’s relationship with the Houston Spaceport began in January 2025, when it conducted its first U.S. pilot launch. During the five-hour mission, the balloon reached an altitude of about 85,000 feet and traveled about 250 miles across Texas.

One of Involve Space’s first U.S. customers is Houston-based Rhodium Scientific, a space biotech company. Polotto and Rhodium Scientific founder and CEO Olivia Gamez Holzhaus signed a deal to conduct biotech experiments aboard Involve Space’s stratospheric balloon platforms before planned missions to orbit.

“The presence of innovative platforms like those developed by Involve strengthens the Spaceport’s role as a site for testing, validating, and deploying advanced technologies between aeronautics and space,” Jim Szczesniak, director of aviation for Houston Airports, added in the release.

View All Listings